JS Link Inc, formerly DNA Link Inc, is a Korea-based company mainly engaged in the genome analysis business. The Company mainly engages in the research and development of genome analysis services and personal genome analysis service products used for disease prevention, diagnosis, and treatment. The Company also mainly engages in the manufacture and sale of coronavirus disease 2019 (COVID-19) diagnostic kits. In addition, the Company engages in the research and development of â€˜Avatar Mouse,â€™ an anticancer drug efficacy evaluation system using the mouseâ€™s biological system.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-06-17	35,000.00 ₩	-3.05%	88,252
26-06-16	36,100.00 ₩	+1.12%	78,686
26-06-15	35,700.00 ₩	+8.35%	154,417
26-06-12	32,950.00 ₩	+0.30%	120,146
26-06-11	32,850.00 ₩	+6.31%	80,663

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Korea S.E. Other stock markets 2026-06-17			5-day change	1st Jan Change
35,000.00 ^KRW	-3.05%		+13.27%	+96.08%

05-15	JS Link, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-12	JS Link, Inc. announced that it expects to receive KRW 5 billion in funding	CI

Market Cap	1,219B 805M 694M 638M 601M 1.13B 75.95B 1.14B 7.56B 2.94B 37.27B 3.02B 2.96B 129B	P/E 2024	-10.5x	P/E 2025	-29.7x
Enterprise Value	1,222B 807M 696M 640M 602M 1.13B 76.13B 1.14B 7.58B 2.95B 37.36B 3.03B 2.96B 129B	EV / Sales 2024	8.93x	EV / Sales 2025	29.6x
Free-Float	74.14%	Yield 2024 *	-	Yield 2025	-

05-15	JS Link, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-12	JS Link, Inc. announced that it expects to receive KRW 5 billion in funding	CI
05-12	JS Link, Inc. announced that it expects to receive KRW 30 billion in funding	CI
03-23	JS Link, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02-02	JS Link, Inc. announced that it has received KRW 20.00000805 billion in funding from Orbitech Co., Ltd., Joosung Sea & Air Co. Ltd	CI
11-14	JS Link, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-02	Malaysia PM says $142 million magnet plant to boost rare earth sector, state media reports	RE
25-10-28	JS Link, Inc. announced that it has received KRW 20.000005568 billion in funding from B & P Joosung Corp.	CI
25-10-01	JS Link, Inc. announced that it has received KRW 12 billion in funding	CI
25-09-21	JS Link, Inc. announced that it expects to receive KRW 12 billion in funding	CI
25-09-03	JS Link, Inc. announced that it has received KRW 7 billion in funding	CI
25-08-05	JS Link, Inc. announced that it expects to receive KRW 8 billion in funding	CI
25-07-31	JS Link, Inc. announced that it has received KRW 10.1 billion in funding	CI

1 day	-3.05%
1 week	+13.27%
Current month	-15.56%
1 month	-1.69%
3 months	-12.61%
6 months	+103.25%
Current year	+96.08%

JS Link, Inc. Stock

Stocks

A127120

KR7127120004

Biotechnology & Medical Research

Valuation: JS Link, Inc.

Chart: JS Link, Inc.

Latest news : JS Link, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: JS Link, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	32,050	37,250
1 month	27,950	43,100
Current year	16,230	49,900
1 year	8,950	49,900
3 years	1,775	49,900
5 years	1,775	49,900
10 years	1,775	49,900

Manager	Title	Age	Since
Jun-Young Lee CEO	Chief Executive Officer	58	2024-08-22
Cheol-Gu Sim CEO	Chief Executive Officer	47	2023-10-19
Kenji Gonishi PRN	Corporate Officer/Principal	58	2024-08-22

Director	Title	Age	Since
Jong-Bin Baek BRD	Director/Board Member	47	2024-08-22
Cheol-Gu Sim BRD	Director/Board Member	47	2023-10-19
Jun-Young Lee BRD	Director/Board Member	58	2024-08-22

Date	Insider	Type	Quantity	% Market Cap.
11-18	Jin-soo Park	Buy	1,500	0.0047%
11-16	Jin-soo Park	Buy	5,000	0.0157%
11-03	Jin-soo Park	Buy	87,138	0.2742%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
JS LINK, INC.	-3.05%	+13.27%	+266.88%	+900.00%	800M
LONZA GROUP AG	-1.05%	-0.71%	-12.71%	-11.02%	43.44B
REVOLUTION MEDICINES, INC.	+2.80%	+7.90%	+303.26%	+527.02%	33.54B
IQVIA HOLDINGS INC.	-1.75%	-5.83%	+10.28%	-20.67%	28.48B
BEONE MEDICINES AG	+3.38%	+4.18%	+7.26%	+41.54%	29.2B
CELLTRION, INC.	+0.06%	+4.36%	+13.31%	+21.11%	25.34B
ASCENDIS PHARMA A/S	+2.05%	+8.49%	-	-	14.36B
MEDPACE HOLDINGS, INC.	-0.05%	-3.04%	+52.18%	+104.46%	13.05B
EUROFINS SCIENTIFIC SE	-0.77%	-3.54%	+2.58%	+3.43%	12.67B
IONIS PHARMACEUTICALS, INC.	+1.02%	+2.49%	+104.43%	+84.22%	12.28B
Average	+0.31%	+1.85%	+83.05%	+183.34%	21.32B
Weighted average by Cap.	+0.67%	+1.37%	+63.74%	+108.24%

	2024	2025
Net sales	15.91B 10.5M 9.06M 8.33M 7.84M 14.74M 991M 14.86M 98.74M 38.44M 487M 39.43M 38.58M 1.68B	19.32B 12.76M 11M 10.12M 9.52M 17.89M 1.2B 18.04M 120M 46.68M 591M 47.87M 46.85M 2.04B
Net income	-10.8B -7.13M -6.15M -5.66M -5.32M -10.01M -673M -10.09M -67.04M -26.1M -330M -26.77M -26.2M -1.14B	-16.45B -10.86M -9.37M -8.61M -8.11M -15.23M -1.02B -15.36M -102M -39.74M -503M -40.76M -39.89M -1.74B
Net Debt	14.39B 9.5M 8.2M 7.54M 7.1M 13.33M 897M 13.44M 89.33M 34.78M 440M 35.67M 34.91M 1.52B	2.88B 1.9M 1.64M 1.51M 1.42M 2.67M 180M 2.69M 17.88M 6.96M 88.13M 7.14M 6.99M 305M